This suggests that treating PBMCs with anti-PD-1 could enhance CTL-mediated anti-tumor responses, not only because this antibody blocks inhibitory signals from PD-1/PD-L1 interactions, but also because it upregulates HLA-DR expression, probably promoting a positive feedback loop of cytokine release and sustained activation (Figure 6). Here, PDCD1 is linked to neoplasm.